AA
INMB icon

ALPS Advisors’s INmune Bio INMB Stock Holding History

ALPS Advisors’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,363
Closed -$155K – 1063
2022
Q1 		$155K Sell
18,363
-2,287
-11% -$20.5K ﹤0.01% 815
2021
Q4 		$211K Sell
20,650
-1,049
-5% -$15.5K ﹤0.01% 871
2021
Q3 		$421K Buy
21,699
+2,036
+10% +$39.3K ﹤0.01% 522
2021
Q2 		$345K Buy
+19,663
New +$265K ﹤0.01% 718

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ALPS Advisors's INMB Position: Q2 2022 in Review

ALPS Advisors sold out of INmune Bio (INMB) in Q2 2022, closing a stake of 18,363 shares — an estimated $155K sold.

ALPS Advisors first reported a position in INMB in Q2 2021 and held it in 4 quarters. The position peaked at $421K in Q3 2021. 36 funds tracked by Wall St. Rank hold INMB as of Q2 2022.

  • ALPS Advisors reported no remaining INmune Bio position as of Q2 2022 after selling out during the quarter.
  • ALPS Advisors sold 18,363 INmune Bio shares in Q2 2022, an estimated $155K.
  • ALPS Advisors first reported a position in INmune Bio in Q2 2021 and held it in 4 quarters.
  • ALPS Advisors's INmune Bio position peaked at $421K in Q3 2021.
  • 36 funds tracked by Wall St. Rank held INmune Bio as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.